Follow Us GraphicFacebook IconTwitter IconLinkedIn Icon
Search Graphic

Expert Financial Analysis and Reporting

Cytokinetics: More Thoughts on the Potential for a Phase 3 Trial of Tirasemtiv in ALS (CYTK, Buy, $4.20)

Investment Thesis

In listening carefully to Cytokinetics’ (CYTK) comments over the last three months, I am convinced that the Company will…
Read more…

Cytokinetics: Tirasemtiv May Still Be Successfully Developed in ALS (CYTK, Buy, $4.77)

I think that there is a strong possibility that Cytokinetics (to the surprise of Wall Street) could announce sometime in…
Read more…

Cytokinetics: I Think That the Company May Decide to Do A Phase 3 Trial with Tirasemtiv (CYTK, $4.70, Buy, For Subscribers Only)

Overview on Clinical Status of Tirasemtiv

I believe that Cytokinetics (CYTK) will decide to move tirasemtiv into phase 3 registration trials…
Read more…

Cytokinetics: There Yet May Be a Path Forward to Develop Tirasemtiv in ALS (CYTK, Buy, $4.49, Paid Subscribers)

Overview

Cytokinetics held a conference call on the results of the BENEFIT-ALS trial on the morning of April 30. The Company…
Read more…

Cytokinetics: The Critical Phase 2b Results for Tirasemtiv Should be Released on April 29th (CYTK, $8.88, Buy, Paid Subscribers Only)

Phase 2b Data on Tirasemtiv will be Presented on April 29th

Cytokinetics has an extremely important binary event upcoming as the…
Read more…

Cytokinetics: Institutional Investors Give BENEFIT-ALS Potential Results a Vote of Confidence (CYTK, $9.06)

Cytokinetics (CYTK) announced that it has completed an equity offering in which it issued 4.375 million shares at a price…
Read more…

Cytokinetics: An In-Depth Look at the Potential for Success of Tirasemtiv in the BENEFIT-ALS Trial in ALS Patients (CYTK, $9.50) (Subscribers Only)

Purpose of This Report

The biggest clinical trial event in all of biotechnology for 2014 could be the reporting of phase…
Read more…